Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: CIHR Fellowship

Direct Payment

$100,000.00

Synergistic application of Positron Emission Tomography (PET) and Magnetic Resonance Spectroscopic Imaging (MRSI) for accurate tumor delineation in radiation therapy treatment planning of glioblastomas

EF 2020-21

Résumé
Glioblastoma is the most aggressive and lethal type of brain cancer accounting for 50% of all brain tumors. Despite extensive research aiming to improve GBM treatment, treatment efficacy is still extremely poor and the current 5-year survival rate is only 5.5%. The standard treatment protocol of GBM includes surgery to resect as much of the tumor as possible without compromising cerebral function followed by chemotherapy and radiation therapy (RT). RT aims at achieving tumor cell kill trough high energy radiation from an external source. To avoid radiation-induced damage to the healthy brain cells while maximizing radiation dose to active tumor cells, RT requires a treatment planning with high precision delineation of tumor extent. In spite of significant advances in RT methods for precise dose delivery, RT treatment planning still relies on conventional MRI. The latter cannot always discriminate between some of secondary tumor effects such as edema and hemorrhage which mimic tumor properties. Furthermore, parts of the tumor cells may have similar appearance to normal tissue which leads to poor tumor delineation and degradation of the treatment efficacy. GBM tumor cells have distinctive metabolic properties compared to the normal brain tissue and my research proposal is to use a combination of molecular imaging techniques, which includes Positron Emission Tomography (PET) and Magnetic Resonance Spectroscopic Imaging (MRSI) to map the metabolic activity of the brain to be used for tumor delineation rather than the conventional structural MRI. A fast and effective workflow for tumor delineation based on molecular and quantitative imaging will be developed and assessed on a cohort of patients with Glioblastoma. If successful, this technique can not only change the current clinical practice in RT treatment planning, but also enable many new applications in the clinical management of glioblastoma, including diagnostics, grading, and assessment of response to therapy.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
Massachusetts, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
440379
Name
Nosrati Reyhaneh
Region
Massachusetts
Country
United States of America
Orgtype
Research Institution
Instname2
Cancer Research
Theme2
Clinical
Prcname2
Fellowships - Post-PhD
Projecttitle
Synergistic application of Positron Emission Tomography (PET) and Magnetic Resonance Spectroscopic Imaging (MRSI) for accurate tumor delineation in radiation therapy treatment planning of glioblastomas
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Brain Tumor; Glioblastoma (Gbm); Gross Tumor Volume (Gtv); Magnetic Resonance Spectroscopic Imaging (Mrsi); Metabolic Imaging; Positron Emission Tomography (Pet); Quantitative Mri; Radiation Therapy; Radiation Therapy Treatment Planning; Tumor Delineation
Abstract
Glioblastoma is the most aggressive and lethal type of brain cancer accounting for 50% of all brain tumors. Despite extensive research aiming to improve GBM treatment, treatment efficacy is still extremely poor and the current 5-year survival rate is only 5.5%. The standard treatment protocol of GBM includes surgery to resect as much of the tumor as possible without compromising cerebral function followed by chemotherapy and radiation therapy (RT). RT aims at achieving tumor cell kill trough high energy radiation from an external source. To avoid radiation-induced damage to the healthy brain cells while maximizing radiation dose to active tumor cells, RT requires a treatment planning with high precision delineation of tumor extent. In spite of significant advances in RT methods for precise dose delivery, RT treatment planning still relies on conventional MRI. The latter cannot always discriminate between some of secondary tumor effects such as edema and hemorrhage which mimic tumor properties. Furthermore, parts of the tumor cells may have similar appearance to normal tissue which leads to poor tumor delineation and degradation of the treatment efficacy. GBM tumor cells have distinctive metabolic properties compared to the normal brain tissue and my research proposal is to use a combination of molecular imaging techniques, which includes Positron Emission Tomography (PET) and Magnetic Resonance Spectroscopic Imaging (MRSI) to map the metabolic activity of the brain to be used for tumor delineation rather than the conventional structural MRI. A fast and effective workflow for tumor delineation based on molecular and quantitative imaging will be developed and assessed on a cohort of patients with Glioblastoma. If successful, this technique can not only change the current clinical practice in RT treatment planning, but also enable many new applications in the clinical management of glioblastoma, including diagnostics, grading, and assessment of response to therapy.
Competitiondate
202012
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Nosrati, Reyhaneh
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $100,000~ $0~